Isomorphic Labs, a DeepMind spinoff, is advancing AI-designed drugs to human trials—marking the first time an AI-discovered medicine reaches this stage of real-world testing

Isomorphic Labs, founded by former DeepMind researchers, has built a pipeline of new medicines designed by artificial intelligence and is now moving them into human trials—the phase where drugs are tested on actual patients rather than in labs or computer models.

Unlike traditional drug discovery, which relies on chemists manually testing thousands of compounds over years, Isomorphic uses AI to predict which molecular structures will work as medicines, compressing the early-stage research from years into months. This AI approach reduces guesswork in identifying candidate drugs before they enter expensive human testing.

For patients and the pharmaceutical industry: if AI-designed drugs succeed in human trials, it proves that AI can shorten the path from lab discovery to approved medicine, potentially bringing treatments to market faster and at lower cost—especially valuable for rare diseases where traditional drug development isn't economically justified.